Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Novo stock crashes after CagriSema misses weight-loss goal
The next-gen obesity prospect failed to achieve the level of weight loss targeted by executives, wiping 19% off the value of the Danish drugmaker.
Nick Paul Taylor
Dec 20, 2024 8:15am
Antag secures $84M series A for GLP-1 add-on
Dec 4, 2024 3:00am
Biohaven fails phase 3 SMA test but plans talks with FDA
Nov 25, 2024 9:56am
Hidden data on obesity prospect wipe $12B off Amgen market cap
Nov 13, 2024 6:35am
Boehringer drops obesity drug from Gubra partnership
Oct 31, 2024 1:22pm
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Sep 24, 2024 7:00am
